Civitas raises $38M to advance drug for Parkinson's complication

09/12/2013 | American City Business Journals

A Series B funding round has brought in $38 million for Chelsea, Mass.-based biotech firm Civitas Therapeutics. Civitas plans to use the money to support clinical development of its experimental drug CVT-301, which is under development for debilitating motor fluctuations in Parkinson's disease patients.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR